Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) Trading Down 6.6% – Here’s What Happened
by Mitch Edgeman · The Markets DailyZomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM – Get Free Report) shares were down 6.6% during trading on Monday . The stock traded as low as C$0.29 and last traded at C$0.29. Approximately 4,800 shares changed hands during trading, an increase of 68% from the average daily volume of 2,858 shares. The stock had previously closed at C$0.31.
Zomedica Pharmaceuticals Corp. (ZOM.V) Price Performance
The firm has a market cap of C$36.73 million and a price-to-earnings ratio of -2.61. The stock has a 50-day moving average price of C$0.29 and a 200 day moving average price of C$0.28. The company has a debt-to-equity ratio of 4.91, a current ratio of 15.31 and a quick ratio of 15.25.
About Zomedica Pharmaceuticals Corp. (ZOM.V)
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination.
See Also
- Five stocks we like better than Zomedica Pharmaceuticals Corp. (ZOM.V)
- CSE: ALEN.U is targeting a fast-growing digital wellness market
- New Copper-Rich “Kraken” Zone Discovered
- 3 Signs You May Want to Switch Financial Advisors
- Your name isn’t on our protected list yet
- Silver paying 20% dividend. Plus 68% share gains